293 filings
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
10-K
2023 FY
RVPH
Reviva Pharmaceuticals Holdings Inc.
Annual report
15 Apr 24
8:22am
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
8:20am
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Results of Operations and Financial Condition
7:45am
NT 10-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
2 Apr 24
Notice of late annual filing
8:00am
SC 13D/A
0v2rg35m j3xhy
16 Feb 24
REVIVA PHARMACEUTICALS / Bhat Laxminarayan ownership change
4:32pm
SC 13G/A
gdm 1f9ezxasve7v
14 Feb 24
REVIVA PHARMACEUTICALS / TANG CAPITAL PARTNERS ownership change
4:00pm
SC 13G
ngtkvx3c83df2qjr7
14 Feb 24
REVIVA PHARMACEUTICALS / ARMISTICE CAPITAL ownership change
3:52pm
EFFECT
5x4f 51xu1p
14 Feb 24
Notice of effectiveness
12:15am
424B4
uw5aok2y3c u3
13 Feb 24
Prospectus supplement with pricing info
5:00pm
CORRESP
edi6sw1b4k dn
9 Feb 24
Correspondence with SEC
12:00am
UPLOAD
ksdp5n zf
9 Feb 24
Letter from SEC
12:00am
SC 13D/A
ap6j8 j6dp4k
30 Nov 23
REVIVA PHARMACEUTICALS / VEDANTA PARTNERS ownership change
4:49pm
4
z5ipvhhw19 6ipg5lm
22 Nov 23
REVIVA PHARMACEUTICALS / PARAG SAXENA ownership change
6:28pm
8-K
mmf1rtwgkx
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering PricedĀ At-the-MarketĀ Under Nasdaq Rules
4:05pm
424B5
0vggx5xe9pporzj40m5
17 Nov 23
Prospectus supplement for primary offering
4:03pm
8-K/A
11eupy5
14 Nov 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
8qqwqoq
14 Nov 23
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:12pm
8-K
b99z t21d7
14 Nov 23
Submission of Matters to a Vote of Security Holders
12:00am